Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
18.96
+0.06 (0.32%)
Nov 5, 2025, 4:00 PM EST - Market closed
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Avadel Pharmaceuticals plc
| Country | Ireland |
| Founded | 2015 |
| IPO Date | Jun 7, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Gregory Divis |
Contact Details
Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland | |
| Phone | 353 1 901 5201 |
| Website | avadel.com |
Stock Details
| Ticker Symbol | AVDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001012477 |
| CUSIP Number | 05337M104 |
| ISIN Number | US05337M1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer and Director |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer and Chief Financial Officer |
| Jerad G. Seurer | General Counsel, Company Secretary and Compliance Officer |
| Susan Rodriguez | Chief Operating Officer |
| Gregory J. Davis | Vice President of Corporate and Business Development |
| Mark W. Elrod | Vice President of Sales |
| Angie Woods | Vice President of People and Culture |
| Dr. Jordan S. Dubow M.D., Ph.D. | Consultant |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations |
| Jennifer Gudeman PharmD | Senior Vice President of Medical and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2025 | 10-Q | Quarterly Report |
| Nov 4, 2025 | 8-K | Current Report |
| Oct 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 22, 2025 | 8-K | Current Report |
| Oct 22, 2025 | 8-K | Current Report |
| Sep 17, 2025 | 8-K | Current Report |
| Sep 3, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |